- Home
- KINS vs INZY Comparison
KINS vs INZY Comparison
Compare KINS & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- INZY
- Stock Information
- Founded
- KINS 1886
- INZY 2015
- Country
- KINS United States
- INZY United States
- Employees
- KINS N/A
- INZY N/A
- Industry
- KINS Property-Casualty Insurers
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- KINS Finance
- INZY Health Care
- Exchange
- KINS Nasdaq
- INZY Nasdaq
- Market Cap
- KINS 197.1M
- INZY 188.2M
- IPO Year
- KINS N/A
- INZY 2020
- Fundamental
- Price
- KINS $16.25
- INZY $1.25
- Analyst Decision
- KINS Strong Buy
- INZY Strong Buy
- Analyst Count
- KINS 1
- INZY 8
- Target Price
- KINS $6.50
- INZY $17.75
- AVG Volume (30 Days)
- KINS 271.4K
- INZY 677.6K
- Earning Date
- KINS 03-26-2025
- INZY 03-11-2025
- Dividend Yield
- KINS N/A
- INZY N/A
- EPS Growth
- KINS N/A
- INZY N/A
- EPS
- KINS 1.34
- INZY N/A
- Revenue
- KINS $149,645,312.00
- INZY N/A
- Revenue This Year
- KINS N/A
- INZY N/A
- Revenue Next Year
- KINS $37.25
- INZY N/A
- P/E Ratio
- KINS $12.16
- INZY N/A
- Revenue Growth
- KINS 3.44
- INZY N/A
- 52 Week Low
- KINS $2.97
- INZY $1.24
- 52 Week High
- KINS $19.18
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- KINS 45.60
- INZY 31.42
- Support Level
- KINS $17.61
- INZY $1.24
- Resistance Level
- KINS $19.18
- INZY $1.43
- Average True Range (ATR)
- KINS 1.00
- INZY 0.10
- MACD
- KINS -0.13
- INZY 0.04
- Stochastic Oscillator
- KINS 4.84
- INZY 3.12
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.